Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.
Behavioral cough suppression therapy may be effective in patients with refractory and unexplained chronic cough (RCC and UCC).
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...
There are no approved therapies for the treatment of chronic cough in IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough affects approximately ...
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results